Previous 10 | Next 10 |
2023-10-25 08:44:46 ET Losers: Sonnet BioTherapeutics Holdings ( SONN ) -35% announces pricing of $4.55 Million underwritten public offering . Alphatec Holdings ( ATEC ) -18% prices $150M stock offering at $10.50 per share. MAIA Biotechnology ( MAIA ...
2023-10-24 08:45:00 ET Palm Beach, FL – October 24, 2023 – FinancialNewsMedia.com News Commentary – Acute myeloid leukemia (AML) is a type of hematologic cancer that is distinguished by the clonal growth of myeloid blasts in the peripheral blood, bone marrow...
2023-10-24 08:23:16 ET Losers: INVO Bioscience ( INVO ) -19% . Markforged Holding Corporation ( MKFG ) -18 % schedules third Quarter 2023 earnings announcement ; provides preliminary third Quarter results and updates 2023 revenue guidance. IonQ ( IONQ...
View the video: https://youtu.be/23WqSM9gI40 CEL-SCI Corporation (NYSE American: CVM) today released a video presentation in which the Company’s CEO, Geert Kersten, shares the most recent data presented at the European Society for Medical Oncology (ESMO) Congres...
2023-10-23 15:35:21 ET More on Cel-Sci Seeking Alpha’s Quant Rating on Cel-Sci Historical earnings data for Cel-Sci Financial information for Cel-Sci For further details see: CEL-SCI climbs after ESMO data for lead asset Multikine
2023-10-23 13:18:40 ET Gainers: LumiraDx Limited ( LMDX ) +186% . Akumin ( AKU ) +178% . Textainer Group Holdings Limited ( TGH ) +44% . Cel-Sci Corp. ( CVM ) +41% . ImmunoPrecise Antibodies Ltd ( IPA ) +27% . Soluna Holdings...
2023-10-23 12:19:40 ET DENVER, Colo., Oct. 23, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; LumiraDx Ltd (NASDAQ: LMDX), CEL-SCI Corp (AMEX: CVM), Inpixon (NASDAQ: INPX), INVO Bioscience Inc (NA...
Target patient population for regulatory submissions finalized: Patients with low PD-L1 , in contrast to current checkpoint inhibitors which work best with high PD-L1. Addressing unmet need in ~145,000 head and neck cancer patients per year worldwide. Routine cancer sc...
Achieves significant milestones toward commissioning of manufacturing facility in preparation for Biologics License Application for regulatory approval submissions CEL-SCI Corporation (NYSE American: CVM) today reported that its Multikine* (Leukocyte Interleukin, Injection) cGMP s...
CEL-SCI will present the MHRA with new results that demonstrate pre-surgical response rates and overall survival advantages that are superior to those published by CEL-SCI previously, as a result of an improved selection algorithm that more accurately predicts the patients who would benef...
News, Short Squeeze, Breakout and More Instantly...
Cel-Sci Corporation Company Name:
CVM Stock Symbol:
NYSE Market:
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from the U.S. Food and D...
CEL-SCI Corp (NASDAQ:CVM) shares are trading higher by 18.6% to $1.98 during Wednesday’s session after the company received positive feedback...
Critical milestone achieved—the FDA accepted CEL-SCI’s selection criteria defining the Multikine target population before surgery Selected patient population had 73% survival with Multikine vs. 45% without Multikine based on analysis of completed 928-patient Phase 3 rand...